IBEX011, the first Nagoya-compliant GMP iboga extract, is now available for clinical use and academic research
20 May 2024
VANCOUVER, BC, May 20, 2024 /PRNewswire/ - Today, Terragnosis Inc., a Canadian drug development company, announced IBEX011, the first GMP extract of Tabernanthe iboga available for use in ibogaine clinics and academic research. IBEX011 also marks the first time that an ibogaine product is compliant with the Nagoya protocol, a UN treaty which ensures equitable benefits for traditional knowledge holders from the Bwiti tradition in Gabon.
Continue Reading
Preview
Source: PRNewswire
Imaged used courtesy of Yann Guignon, Blessings of the Forest Gabon. (CNW Group/Terragnosis Inc.)
Iboga root bark has been used for millennia for traditional healing and initiation rites, and more recently in international clinics that treat drug addiction and neurological conditions, including traumatic brain injury. Ambio Life Sciences, the world's largest medical ibogaine facility, treating over 50 patients a month, will be the first clinic to use Terragnosis' iboga extract with patients.
Jonathan Dickinson, the CEO of both Terragnosis and Ambio, said, "This marks a common-sense shift in how we think about the production of psychedelic medicine. We've gone back to the source to build relationships with the most experienced practitioners. Our goal is to offer the product with the most potent healing properties."
While most ibogaine in use today is produced semi-synthetically using chemicals extracted from alternative plant sources, IBEX011 contains all of the naturally occurring alkaloids found in T. iboga root bark. This new extract is at least 30% stronger by weight than single molecule ibogaine products.
"What we've seen so far has surprised us," said Ambio co-founder and Chief Operations Officer Trevor Millar. "We're excited to demonstrate what a standardized botanical like this will mean for the healing and optimization of our patients."
Terragnosis' iboga is sourced from the A2E Association in Ebyeng, a Fang community in northeastern Gabon. The story of Aloïse Amougou, whose visionary insight to begin planting iboga came after his own initiation 20 years ago, was the subject of a 2023 feature story in National Geographic.
The architecture of Gabon's Nagoya strategy was developed and implemented by Blessings of the Forest (BoTF), a non-profit dedicated to the preservation and development of Gabonese cultural and natural heritage. A2E is the first of 20 farms financed by BoTF, and after a decade of work the project promises to set a new precedent for access and benefits sharing in psychedelic production and the pharmaceutic industry.
SOURCE Terragnosis Inc.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.